Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SirJoke-What is the link and date please?
Posted by: SirJoke - “In a separate but related piece from Reuters.com,”
I KEEP SAYING DON’T DUMP YOUR SHARES- I just bought a pile @ .0251 –it’s to good a price not to!!
makinmoney777 If you cannot make a profit in this “ bad” stock and it sounds like you don’t own any (do you?) (If so how much and at what price?). but if not. then what is your purpose for all your negative input?
“Safe Harbor” maybe where the baby that got thrown out with the bath water. ASFX needs to do something fast before they lose a pile of loyel investers!
"The Company is pleased” “pleased to make available its audited reports” I wish I FELT pleased!
American Scientific Resources Inc. Discloses Audited Financials for 2007 and 2008Last update: 10/8/2009 3:24:00 PMWESTON, Fla., Oct 08, 2009 /PRNewswire via COMTEX/ -- American Scientific Resources Inc. (PINK SHEETS: ASFX) is pleased to make available its audited reports for the periods ending December 31, 2007 and December 31, 2008. These reports may be viewed in full at . American Scientific Resources, Inc., , is a leading provider of innovative next-generation, health, medical, and safety products distributed primarily through nationwide retailers, medical suppliers, infomercials and on-line sites. Previously the Company had their 2007 financials audited, and decided to have them re-audited so that they were even more comprehensive. CEO and Chairman of the Board for ASR, Dr. Christopher F. Tirotta commented, "The Company is pleased to have been able to complete and file the statements for 2007 and 2008 for current and potential shareholder due diligence. We are well aware of the challenges that we have faced over the recent years and are grateful for the continuing support of all our shareholders and those who have helped the Company thus far. The Company has made outstanding progress in recent weeks and we will keep shareholders informed of our developments in the days to come."
How about .05 today?
Maybe 1% that don’t live on the street- lots of family money?
ShotsII -Your right- Thank You
Getting back to the real issues is the bashing that undermines ASFX value. Its suspect to me when someone hangs around a site to tear a stock down with supposedly no interest in owning it!
Junkies may someday have accesses to the NDD and they can hit a vein
Why does “makinmoney777” get his postings in BOLD type?
What’s your point?
Good buy time – this is a good fishing spot, take a boat load at these prices! BDkeg I think the tooth fairy will be the only way you will get .01
Sellers are in a panic – the day may go up and down – but the stock will go up
Someone is buying while a lot are waiting for the smoke to clear – but then it will be back in the 5’s
I agree
You should--it not going to keep going down enough to miss out when it starts going straight up!
WAS THAT A JOKE OR REAL NEWS –SITE?
DVAX-
10/1/09 - Dynavax initiates Phase III registration trial of hepatitis B vaccine
Oct 01, 2009 (Datamonitor via COMTEX) Dynavax Technologies, a clinical-stage biopharmaceutical company, has started a Phase III registration trial for Heplisav hepatitis B vaccine in individuals with chronic kidney disease.
http://www.pharmacychoice.com/News/article.cfm?Article_ID=464252
Going along with that, look at the market the last 2 days!
September 27, 2009 | about: AGEN
Nothing has changed with the potential of Antigenics (AGEN) and its stock. If anything, the longer it trades for a price of near two dollars, the better buy it becomes because the closer news is to being released.
I've mentioned before that AGEN is one of the few stocks that I am willing to average-up in and I will continue to do so as long as the price is right. In my opinion, the next big move will push the stock to over five dollars, but eventually I consider this one to be another DNDN.
http://seekingalpha.com/article/163576-have-to-like-the-risk-reward-in-antigenics-stock
http://www.pharmacychoice.com/news/article.cfm?Article_ID=461152
9/28/09 - American Scientific Resources Acquires Intellectual Property to World's Only FDA Approved Home Needle Destruction Device
2009 SEP 28 - (NewsRx.com) American Scientific Resources, Inc. (Pink Sheets: ASFX) (the Company), is excited to announce that it has acquired the intellectual property to the world's only FDA approved home needle destruction device (NDD), the Disintegrator? and Disintegrator Plus? (U.S. Patent No. 6,384,362 Patent Application No.: 09/500,504) (the "Device Technology") (see also Diabetes).
A formerly owned property of Safeguard Medical Technologies, American Scientific Resources now holds the rights to the patent, which includes the Device Technology Patent and all present and future developed information, knowledge, experience and results.
As part of the agreement, all current contracts and future sales and contracts pertaining to the Device Technology are the sole property of ASR. Rights to such sales are worldwide with the exception of a single licensing agreement covering the European Union region where Safeguard pays a consulting royalty on sales.
Safeguard will receive stock, warrants, a convertible note and cash payments based on sales performance. They will also provide ongoing production engineering and quality control services to ASR for a fee.
ASR's plan is to introduce the product commercially in the fall/winter of 2009. The Disintegrator enables patients who give themselves injections, including those suffering from multiple sclerosis or diabetes, to properly and safely dispose of needles at home. The EPA and the American Diabetes Association approve the device.
Dr. Christopher F. Tirotta, CEO of American Scientific Resources, states, "We are overjoyed to have acquired the property rights to a product that we think has enormous potential to be a worldwide leader in home needle destruction. The product has already received a warm reception in the market."
Safeguard delivered a purchase order for 5000 units to one of the world's leading healthcare enterprises in March of 2009; since then, the global enterprise has placed an additional order for 2000 units which American Scientific Resources will fill. Safeguard practices a form of just-in-time productivity, matching production to its needs based on order size. Production is planned to ramp up by year's end with full production capability exceeding 25,000 units per month.
California State Senator Joe Simitian announced recently that his bill, SB 486, is headed to the Governor for review. The bill is designed to facilitate the safe disposal of syringes and needles (also known as "sharps") by requiring pharmaceutical manufacturers who sell specialty drug medications for home use to provide information on their websites on safe needle collection and disposal programs for their drugs. Over one million Californians who use specialty injection drugs don't have a safe, legal way to dispose of their sharps. Hence, approximately 386-million sharps are generated each year in California that need to be disposed of.
"Given the need in the US for a safe way to dispose of sharps, we are hopeful that the Disintegrator will eventually become a trusted household name," continues Dr. Tirotta.
Additionally, a congressional bill (S, 1312) is pending which would amend Title XVIII of the Social Security Act to provide for coverage, as supplies associated with the injection of insulin, of containment, removal, decontamination, and disposal of home-generated needles, syringes, and other sharps through a sharps decontamination/destruction device or similar program under part D of the Medicare program.
(c) 2009 Diabetes Week via NewsRx.com
sorry --brezlin – when and where is that posting??
“Gov. Schwarzenegger should sign bill regulating needle disposal”
pennystocksrule – when and where is that posting??
“Gov. Schwarzenegger should sign bill regulating needle disposal”
senderos---you have a link for that? I dont see it
I’m new to this stock. Is SPHRY FDA approved? Is it sold in the US or in other parts of the world? What opinion of price -4.65 to go up or down?
Why can’t I sell EVFL even at a loss of .0001?
Can anyone tell me in realy simple english why you have so much hope in this stock?
And such a following?
please!
Thank You
Ariad Pharmaceuticals, Inc. (ARIA) Says Independent Experts Positive on Cancer Drug
9/15/2009
BCRX up 1.41
Company seems to have “O” concern for share holders!
WHO'S SELLING THIS??? MY OWN SHARES WHERE LISTED WHEN @ .0002 FOR WEEKS AND WOULD NOT MOVE YET VOLUME WAS HIGH EVERY DAY?
WHO'S SELLING THIS???
Only if it’s Billy Beer!
It my however, just keep gradually going up with small dips because what it usually does, it may stop doing. It looks like its usual circumstance’s have changed this last week! I think your “10.00 a share” is reasonable.
Zacks Investment Research
Good News for Dynavax
September 11, 2009 | DVAX
http://www.zacks.com/stock/news/24704/Good+News+for+Dynavax++-+Analyst+Blog
Yesterday, Dynavax Technologies Corp. (DVAX - Analyst Report) announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on its late-stage hepatitis B vaccine (HBV) Heplisav which is being developed for patients suffering from chronic kidney disease.
As a reminder, Heplisav was on clinical hold in the U.S since Mar 17, 2008 following the report of the severe adverse event (SAE) of Wegener's granulomatosis. The SAE was reported in the phase III study in healthy adults conducted outside the U.S. Wegener's granulomatosis is an uncommon disease which results in the inflammation of blood vessels .The vaccine is being studied for both healthy adults and patients with end-stage renal disease.
Consequent to the regulatory issues, the partnership with Merck & Co. Inc. (MRK) for Heplisav ended on December 19, 2008. All rights relating to the development and commercialization of Heplisav reverted to Dynavax.
In October 2008 and February 2009, the FDA requested for additional information prior to considering further development of Heplisav in end-stage renal disease patients (ESRD).
Subsequently, Dynavax presented additional phase III data on Heplisav in April. The data demonstrated the vaccine's potential to provide more rapid and increased protection with fewer doses against HBV than GlaxoSmithKline plc’s (GSK) Engerix-B. Furthermore, the company proposed the continued development of Heplisav in populations less responsive to Engerix-B. The population included adults over 40 years of age, individuals with chronic kidney disease, and other groups such as individuals infected with HIV or diagnosed with chronic liver disease. The FDA agreed to the proposal.
As a result of the removal of the clinical hold, Dynavax intends to start a phase III trial for Heplisav in chronic kidney disease patients soon. Furthermore, it intends to start another late stage trial of the vaccine next year in people over 40 years of age. Management expects the vaccine to hit the market by the end of 2012 or early 2013.
Hepatitis B is a chronic disease which can lead to cirrhosis of the liver and hepatocellular carcinoma. The global market for adult hepatitis B vaccines is estimated at over $500 million annually.
mattybum WHAT IS -the full scope of their total revenues –Is there ASFX – News on that
I’m defiantly holding what I have! NEWS, FDA, whatever, it will be GOOD!!!! –2X-3X 4X$$$???
To buy 816 million volume that look like mostly buys ---Who is SUPPLYING the Shares ??????? Last month at .0002 I tried to sell part of my shares for weeks – not a bite
Company’s website at http://www.ariad.com/investor. A replay of the presentation will be available on the ARIAD website approximately twenty-four hours after the presentation and will be archived for four weeks.
ARIA corporate presentation --webcast ------ http://www.wsw.com/webcast/rrshq15/aria/